Haploinsufficiency of p18INK4c sensitizes mice to carcinogen-induced tumorigenesis

Molecular and Cellular Biology

Volumn 23, Issue 4, 2003, Pages 1269-1277

  Bai, Feng ^a   Pei, Xin Hai ^a   Godfrey, Virginia L ^b   Xiong, Yue ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P18; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FAMILIAL CANCER; GENOTYPE; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN CANCER; SKIN CARCINOGENESIS; TUMOR SUPPRESSOR GENE;

ADENOMA; ANIMALS; CARCINOGENS; CARCINOMA; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DIMETHYLAMINES; ENZYME INHIBITORS; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEMANGIOSARCOMA; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, MUTANT STRAINS; NEOPLASMS, EXPERIMENTAL; PITUITARY NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 0037317415     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.23.4.1269-1277.2003     Document Type: Article

References (41)

1. Bai, F., Y. Nakanishi, K. Takayama, X. H. Pei, H. Tokiwa, and N. Hara. 1998. Ki-ras mutation and cell proliferation of lung lesions induced by 1-nitropyrene in A/J mice. Mol. Carcinog. 22:258-264.
2. Clapp, N. K., A. W. Craig, and R. E. Toya, Sr. 1968. Pulmonary and hepatic oncogenesis during treatment of male RF mice with dimethyl-nitrosamine. J. Natl. Cancer Inst. 41:1213-1227.
3. Cook, W. D., and B. J. McCaw. 2000. Accommodating haploinsufficient tumor suppressor genes in Knudson's model. Oncogene 19:3434-3438.
4. Kip1 is haplo-insufficient for tumor suppression. Nature 396:177-180.
5. KIP1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 12:2899-2911.
6. Franklin, D. S., V. L. Godfrey, D. A. O'Brien, C. Deng, and Y. Xiong. 2000. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol. Cell. Biol. 20:6147-6158.
7. INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. Mol. Biol. Cell 7:1587-1599.
8. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 8:2939-2952.
9. Hall, M., and G. Peters. 1996. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:67-108.
10. Hunter, T., and J. Pines. 1994. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573-582.
11. Inoue, K., F. Zindy, D. H. Randle, J. E. Rehg, and C. J. Sherr. 2001. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev. 15:2934-2939.
12. Jacks, T., A. Fazeli, E. M. Schmitt, R. T. Bronson, M. A. Goodell, and R. A. Weinberg. 1992. Effects of an Rb mutation in the mouse. Nature 359:295-300.
13. Kamb, A., N. A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S. V. Tavitgian, E. Stockert, R. S. Day, B. E. Johnson, and M. H. Skolnick. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
14. Knudson, A. G., Jr. 1985. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 45:1437-1443.
15. Kovalev, G. I., D. S. Franklin, V. M. Coffield, Y. Xiong, and L. Su. 2001. An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation. J. Immunol. 167:3285-3292.
16. Krimpenfort, P., K. C. Quon, W. J. Mooi, A. Loonstra, and A. Berns. 2001. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413:83-86.
17. Kwabi-Addo, B., D. Giri, K. Schmidt, K. Podsypanina, R. Parsons, N. Greenberg, and M. Ittmann. 2001. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA 98:11563-11568.
18. INK4c cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 19:3496-3506.
19. Lee, Y.-H. P., C.-Y. Chang, N. Hu, Y.-C. J. Wang, C.-C. Lai, K. Herrup, W.-H. Lee, and A. Bradley. 1992. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288-294.
20. Lohmann, D. R. 1999. RB1 gene mutations in retinoblastoma. Hum. Mutat. 14:283-288.
21. Nikitin, A. Y., M. I. Juarez-Perez, S. Li, L. Huang, and W. H. Lee. 1999. RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice. Proc. Natl. Acad. Sci. USA 96:3916-3921.
22. Nobori, T., K. Mlura, D. J. Wu, A. Luis, K. Takabayashi, and D. A. Carson. 1994. Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
23. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 55:1448-1451.
24. INK4c expression during myogenesis. Mol. Cell. Biol. 18:2334-2343.
25. Quon, K. C., and A. Berns. 2001. Haplo-insufficiency? Let me count the ways. Genes Dev. 15:2917-2921.
26. Robanus-Maandag, E., M. Dekker, M. van der Valk, M. L. Carrozza, J. C. Jeanny, J. H. Dannenberg, A. Berns, and H. te Riele. 1998. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev. 12:1599-1609.
27. INK4a/CDK2A tumor suppresor and its relatives. Biochim. Biophys. Acta 1378:F115-F177.
28. Sharpless, N. E., N. Bardeesy, K. H. Lee, D. Carrasco, D. H. Castrillon, A. J. Aguirre, E. A. Wu, J. W. Horner, and R. A. DePinho. 2001. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413:8691.
29. Sherr, C. J. 1996. Cancer cell cycle. Science 274:1672-1677.
30. Sotillo, R., P. Dubus, J. Martin, E. de La Cueva, S. Ortega, M. Malumbres, and M. Barbacid. 2001. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 20:6637-6647.
31. Venkatachalam, S., Y. P. Shi, S. N. Jones, H. Vogel, A. Bradley, D. Pinkel, and L. A. Donehower. 1998. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 17:4657-4667.
32. Wang, T. C., R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt. 1994. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671.
33. Weinberg, R. A. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.
34. Williams, B. O., E. M. Schmitt, L. Remington, R. T. Bronson, D. M. Albert, R. A. Weinberg, and T. Jacks. 1994. Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J. 13:4251-4259.
35. Wolfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, M. Buschenfelde, and D. Beach. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284.
36. Yu, Q., Y. Geng, and P. Sicinski. 2001. Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017-1021.
37. INK4c in tumorderived cell lines and primary tumors. Oncogene 12:451-455.
38. INK4d, in tumor-derived cell lines and primary tumors. Oncogene 13:2033-2038.
39. Zhu, Y., P. Ghosh, P. Charnay, D. K. Burns, and L. F. Parada. 2002. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296:920-922.
40. Zindy, F., J. van Deursen, G. Grosveld, C. J. Sherr, and M. F. Rousel. 2000. INK4d-deficient mice are fertile despite testicular atrophy. Mol. Cell. Biol. 20:372-378.
41. Zuo, L., J. Weger, Q. Yang, A. M. Goldstein, M. A. Tucker, G. J. Walker, N. Hayward, and N. C. Dracopoli. 1996. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12:97-99.